StockData
Vir Biotechnology, Inc. logo

Vir Biotechnology, Inc. (VIR) stock

VIRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 11/3030% below fair value
$9.25−0.33 (-3.44%)

Close on Nov 17, 2026Market cap $1.57BP/E –Yield –

Vir Biotechnology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Vir Biotechnology's pe ratio was 6.6× on Apr 28, 2023, against 5.1× a year earlier.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2023Apr 28, 20236.6×+3.6
2022Dec 30, 20223.0×–

More Vir Biotechnology figures

See a number that looks wrong?